TWA
ABUS icon

TCI Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

TCI Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$1.51K – 210
2023
Q1 		$1.51K Hold
500
– – ﹤0.01% 2033
2022
Q4 		$1.17K Hold
500
– – ﹤0.01% 2089
2022
Q3 		$1K Hold
500
– – ﹤0.01% 2016
2022
Q2 		$1K Hold
500
– – ﹤0.01% 2075
2022
Q1 		$1K Buy
500
+300
+150% +$918 ﹤0.01% 2055
2021
Q4 		$1K Buy
+200
New +$777 ﹤0.01% 2146

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TCI Wealth Advisors's ABUS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2023, closing a stake of 500 shares — an estimated $1.51K sold.

TCI Wealth Advisors first reported a position in ABUS in Q4 2021 and held it in 6 quarters. The position peaked at $1.51K in Q1 2023. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Arbutus Biopharma position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 500 Arbutus Biopharma shares in Q2 2023, an estimated $1.51K.
  • TCI Wealth Advisors first reported a position in Arbutus Biopharma in Q4 2021 and held it in 6 quarters.
  • TCI Wealth Advisors's Arbutus Biopharma position peaked at $1.51K in Q1 2023.
  • 111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.